Overview

Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH)

Status:
Unknown status

Trial end date:
2009-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of rosiglitazone alone compared with rosiglitazone plus metformin or rosiglitazone plus losartan in the treatment of biopsy proven nonalcoholic steatohepatitis (NASH). This study was designed to answer the question: are there differences in the efficacy (as measured by histopathology and insulin resistance) of three different therapeutic modalities used to treat NASH?

Phase:

Phase 2

Details

Lead Sponsor:

Brooke Army Medical Center

Treatments:

Losartan
Metformin
Rosiglitazone